At Xylyx Bio, we have developed IN MATRICO™ Fibrosis Assay that incorporates our human derived, disease-specific extracellular matrices as well as corresponding data analytics for anti-fibrotic drug discovery. Our IN MATRICO™ Fibrosis Assay is applicable across multiple stages of the early-stage drug discovery pipeline, from target selection and hit identification through lead identification and optimization.
Read press release
Accelerate and improve drug discovery and screening in IPF with custom IPF-specific ECM substrates, allowing drug candidates to be studies in a human, disease-relevant environment in vitro.
Implement custom NASH-derived ECM substrates into preclinical human disease models and cell-based screening assays to increase clinical relevance and success rates.